The Committee for Medicinal Products for Human Use (CHMP) has recommended that the immunotherapy be approved to treat adults ...

The green light from the European Medicines Agency is the first backing in the EU for the medicine, following its approval in ...

A revival in AstraZeneca Plc shares faces a key test this week, with more likely to hinge on the drugmaker’s ability to ...

AstraZeneca's Imfinzi has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has ...

CORE EARNINGS PER SHARE: Core earnings per share are expected to rise to $2.07 from $1.45 the year prior, according to the same consensus. AstraZeneca's stock is up 7.9% since the start of 2024.

The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...

AstraZeneca PLC (LON:AZN), a leading global biopharmaceutical company with a market capitalization of $216.74 billion, has been making significant strides in the pharmaceutical industry, particularly ...

Roche is the recipient of the new approval, getting the go-ahead from the US regulator for its PATHWAY HER2 (4B5) test to ...

AstraZeneca PLC (LSE/STO/NASDAQ:LON:AZN), a pharmaceutical giant with a market capitalization of $215.44 billion and impressive gross profit margins of 82.61%, has received a recommendation for ...

The approval by the US Food and Drug ... small cell lung cancer (NSCLC) who have received prior systemic therapies, including an EGFR-directed therapy. Alexion Pharma Canada Corp., AstraZeneca's ...

London open The FTSE 100 is expected to open 109 points lower on Monday, having closed up 0.31% on Friday at 8,673.96.